Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Total Current Liabilities data on record, last reported at $61.4 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 47.55% year-over-year to $61.4 million; the TTM value through Sep 2025 reached $61.4 million, up 47.55%, while the annual FY2024 figure was $156.9 million, 236.85% up from the prior year.
  • Total Current Liabilities reached $61.4 million in Q3 2025 per GLUE's latest filing, up from $41.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $156.9 million in Q4 2024 and bottomed at $19.1 million in Q2 2023.
  • Average Total Current Liabilities over 3 years is $50.3 million, with a median of $41.9 million recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: soared 236.85% in 2024, then dropped 1.17% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $46.6 million in 2023, then skyrocketed by 236.85% to $156.9 million in 2024, then tumbled by 60.85% to $61.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $61.4 million in Q3 2025, $41.9 million in Q2 2025, and $59.2 million in Q1 2025.